<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2021-04072-282-12262</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Immunity to malaria: exploring the antibody and memory response to highly polymorphic antigens</narrative>
   <narrative xml:lang="SV">Malaria immunitet: studier av immunsvar mot variabla parasitantigen</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Malaria f&#xF6;rblir ett av de stora globala h&#xE4;lsoproblemen med h&#xF6;g sjuklighet och d&#xF6;dlighet s&#xE4;rskilt hos barn i Afrika s&#xF6;der om Sahara. Ett effektivt vaccin beh&#xF6;vs f&#xF6;r att bek&#xE4;mpa och utrota malaria p&#xE5; sikt. Utmaningen med att utveckla effektiva vaccin mot malaria &#xE4;r att parasiten har stor genetisk variabilitet och att immuniteten &#xE4;r stamspecifik. Dessutom beh&#xF6;ver skyddet kunna uppr&#xE4;tth&#xE5;llas &#xF6;ver tid. Individer som bor i endemiska omr&#xE5;den utvecklar, efter upprepade infektioner, immunitet som skyddar mot all bli sjuk vid n&#xE4;r de smittas med malariaparasiter. Antikroppar &#xE4;r viktiga i detta skydd. En &#xF6;kad f&#xF6;rst&#xE5;else f&#xF6;r hur denna naturliga immunitet utvecklas och bibeh&#xE5;lls och hur antikroppar skyddar mot olika varianter av parasitantigen beh&#xF6;vs f&#xF6;r att v&#xE4;gleda vaccinutvecklingen. Syftet med detta projekt &#xE4;r att studera hur immuniteten mot malaria utvecklas, med fokus p&#xE5; variabla parasitantigenen och uppr&#xE4;tth&#xE5;llande av immunitet. Den genetiska m&#xE5;ngfalden av variabla antigen kommer att studeras i olika geografiska omr&#xE5;den med en ny sekvenseringsmetod. Vidare kommer vi att utrycka antigen som vi kommer att anv&#xE4;nda f&#xF6;r analyser av antikropps- och minnessvar efter malariainfektion och studera hur dessa korrelerar till skydd mot malaria. Studierna kommer att utf&#xF6;ras i Kenya och Tanzania d&#xE4;r barn och vuxna f&#xF6;ljs &#xF6;ver tid med avseende p&#xE5; malariainfektioner, och &#xE4;ven p&#xE5; resen&#xE4;rer behandlade f&#xF6;r malaria i Sverige. Projektet bygger p&#xE5; samarbeten med forskargrupper i Kenya och Tanzania och gemensamma doktorander. Projektet f&#xF6;rv&#xE4;ntas bidra till utveckling av ett effektivt multikomponentvaccin mot malaria.</narrative>
   <narrative xml:lang="EN">Malaria remains a major global health problem with high morbidity and mortality in children in Sub-Saharan Africa. An efficacious vaccine is urgently needed. Vaccine design is challenged by difficulties in identifying the specific antigens against which protective antibodies are directed. Given the extensive diversity of many parasite antigens, immunity is believed to require an antibody repertoire against multiple antigen variants. The aim of this project is to improve the understanding the naturally acquired immunity to malaria, focusing on antigen diversity and maintenance of immunity. The project will explore antigen diversity focusing on polymorphic merozoite surface proteins, in relation to antibody and memory B cell responses and their role in protection. A newly developed sequencing method will allow characterization of antigen diversity across geographical areas, and design of a peptide microarray and recombinant antigens that will be used to investigate the breadth, magnitude and cross-reactivity of antibody responses. Memory B cell responses will be assessed using a newly developed multiplex B cell FluoroSpot method. Studies are performed in longitudinal cohort in Kenya and Tanzania, as well as travelers treated for malaria in Sweden. The project builds on close collaboration between researchers Kenya, Tanzania and Sweden and involves joint PhD students. The overall goal is to contribute to the development of an efficacious multicomponent vaccine against malaria.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-01-01" type="1"></activity-date>
  <activity-date iso-date="2024-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TZ" percentage="100">
   <narrative xml:lang="EN">Tanzania, United Republic of</narrative>
  </recipient-country>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <policy-marker code="5" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">186508.7619069827</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">163190.3135165386</value>
  </budget>
  <budget>
   <period-start iso-date="2024-01-01"></period-start>
   <period-end iso-date="2024-12-28"></period-end>
   <value currency="USD" value-date="2024-01-01">174849.4211195187</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-11-25"></transaction-date>
   <value currency="USD" value-date="2021-11-25">524548.49654304</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
